Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pinterest

- PMLiVE

Novartis’ orphan drug Tasigna wins EU expanded indication

The CML medication can now treat paediatric patients

National Institute for Health and Care Excellence NICE logo

NICE backs two advanced breast cancer drugs after price cuts

An estimated 8,000 women will be eligible to receive the drugs due to discounts

- PMLiVE

Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

Women on Kisqali were found to have a longer PFS than those on hormonal therapy alone

- PMLiVE

Novartis strengthens autoimmune indications for Cosentyx

Data shows its IL-17A inhibitor can reduce structural disease progression

- PMLiVE

Novartis files CAR-T therapy CTL109 in Europe

Analysts predict Kymriah could become a $1bn-plus product in Europe

Pharma’s digital patient engagement innovators identified

Novartis, Pfizer and Sanofi named best-in-class by Decision Resources Group

- PMLiVE

Novartis moves swiftly with lymphoma filing for CAR-T Kymriah

Will go up against Kite Pharma's Yescarta if approved

- PMLiVE

Novartis to buy French radiopharma specialist AAA for $3.9bn

Deal will strengthen its cancer therapy business, says Swiss pharma group

Novartis Gehry Building

Alcon spin-out more likely but not imminent, says Novartis

A stand-alone company could offer “additional shareholder value”

Content Shock

Is your content good enough to power your multi-channel marketing?

Content shock is the time when increasing volumes of content intersect our limited human capacity to consume it.

An agency called Owen

- PMLiVE

Novartis gets EU nod for leukaemia drug Rydapt

The FLT3 inhibitor adds to its US approval in AML

- PMLiVE

Roche faces prospect of second Rituxan biosimilar in US

FDA begins its review of Sandoz's version of the immunotherapy treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links